Dogwood (DWTX) Therapeutics announces the dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP, evaluating Halneuron for the treatment of neuropathic pain associated with prior chemotherapy treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DWTX: